Analysis of the budget impact for the Spanish National Health System of the fixed combination of amlodipine 5 or 10 mg and atorvastatin 10 mg;Análisis del impacto presupuestario para el Sistema Nacional de Salud de la combinación fija de amlodipino 5 o 10 mg y atorvastatina 10 mg

Farmacia Hospitalaria

Volumn 34, Issue 4, 2010, Pages 170-180

  De Salas, M ^a   Fernandez De Bobadilla J ^b   Ferro, B ^c   Rejas, J ^c  

^a Economía e Investigación de Resultados en Salud OYs Integra   (Spain)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^c PFIZER INC   (United States)

Author keywords

Budget impact analysis; Cardiovascular risk; Economic model; Fixed combination of amlodipine atorvastatin; Health costs; Hypertension

Indexed keywords

AMLODIPINE PLUS ATORVASTATIN;

ANTIHYPERTENSIVE THERAPY; ARTICLE; BUDGET; EPIDEMIOLOGICAL DATA; HEALTH CARE; HEALTH CARE COST; HUMAN; HYPERTENSION; SCIENTIFIC LITERATURE;

AMLODIPINE; BUDGETS; CARDIOVASCULAR DISEASES; COST SAVINGS; DECISION TREES; DRUG COSTS; HEPTANOIC ACIDS; HUMANS; HYPERTENSION; MODELS, THEORETICAL; NATIONAL HEALTH PROGRAMS; PYRROLES; SPAIN;

EID: 77954659699     PISSN: 11306343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.farma.2009.11.008     Document Type: Article

References (40)

1. L. Hansson, A. Zanchetti, S.G. Carruthers, W. Kuerrt, J.H. Koller, Z. Beneriont on behalf of HOT Study Group Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial Lancet 351 1998 1755 1762 (Pubitemid 28269185)
2. R. Collins, R. Peto, S. MacMahon, P. Hebert, N.H. Fiebach, and K.A. Eberlein Blood pressure, stroke and coronary disease. Part2, Short term term reductions in blood pressure: overview of randomized drug trials in their epidemiological context Lancet 335 1990 827 828
3. R. Asmar, S. Vol, B. Pannier, A.M. Brisac, J. Tichet, and A. El Hasnaoui High blood pressure and associated cardiovascular risk factors in France J Hypertens 19 2001 1727 1732
4. F.A. Tremollieres, J.M. Pouilles, C. Caunielle, and C. Ribot Coronary heart disease risk factors and menopause: a study in 1684 French women Atherosclerosis 142 1999 415 423
5. F. Thomas, A. Rudnichi, A.M. Bacri, K. Bean, L. Guize, and A. Benetos Cardiovascular mortality in hypertensive in men according to presence of associated risk factors Hypertension 37 2001 1256 1261
6. R.M. Conroy, K. Pyrl, A.P. Fitzgerald, S. Sans, A. Menotti, G. De Backer on behalf of the SCORE Project Group Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project Eur Heart J 24 2003 90387
7. P.S. Sever, B. Dahlof, N.R. Poulter, H. Wedel, G. Beevers, M. Caulfield ASCOT investigators Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial Lipid-Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial Lancet 361 2003 1149 1158 (Pubitemid 36398384)
8. R. Collins, J. Armitage, S. Parish, P. Sleigh, and R. Peto MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised, placebo-controlled trial Lancet 360 2002 7 22 (Pubitemid 34756487)
9. H.M. Colhoun, D.J. Betteridge, P.N. Durrington, G.A. Hitman, H.A. Neil, S.J. Livingstone CARDS investigatores Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo- controlled trial Lancet 364 2004 685 696
10. N.J. Wald, and M.R. Law A strategy to reduce cardiovascular disease by more than 80% BMJ 326 2003 1419
11. M.T. Olalla, M.J. Medrano, M.J. Sierra, and J. Almazn Time trends, cohort effect and spatial distribution of cerebrovascular disease mortality in Spain Eur J Epidemiol 15 1999 331 339
12. M.J. Barrado, M.J. Medrano, and J. Almazn Mortalidad por cardiopata isqumica en Espaa: tendencia y distribucin geogrfica Rev Esp Cardiol 48 1995 106 114
13. M.J. Medrano, J. Aalmazn, M.J. Sierra, and M.T. Olalla Situacin Epidemiolgica de las enfermedades cardiovasculares (I): mortalidad y morbilidad Bol Epidemiol Semanal 6 1998 149 153
14. M.J. Medrano, G. Lpez-Abente, M.J. Barrado, M. Polln, and J. Almazn Effect of age, birth cohort and period of death on cerebrovascular mortality in Spain, 1952 through 1991 Stroke 28 1997 40 44
15. J.R. Banegas, J.C. Alberdi, F. Rodriguez-Artalejo, V. Domnguez, and J. del Rey Calero Age-period-cohort analysis of mortality caused by ischemic cardiopathy in Spain 19651985 Gac Sanit 6 1992 9704
16. G. Prez, A. Pena, J. Sala, P. Roset, R. Masi, and J. Marrugat Acute myocardial infarction case fatality, incidence and mortality rates in a population registry in Gerona, Spain, 19901992 Int J Epidemiol 27 1998 59904
17. H. Tunstall-Pedoe], K. Kuulasmaa, M. Mhnen, H. Tolonen, E. Ruokokoski, and P. Amouyel Contribution of trends in survival and coronary events rates to changes in coronary heart disease mortality: 10 year results from 37 WHO MONICA Project populations (monitoring trends and determinants in cardiovascular disease) Lancet 353 1999 1547 1557
18. P.S. Sever, N.R. Poulter, B. Dahlof, H. Wedel, G. Beevers, M. Caulfield on behalf of the ASCOT investigators Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial Journal of hypert 19 2001 1139 1147
19. P.S. Sever, B. Dahlof, N.R. Poultre, H. Wedel, G. Beevers, and M. Caulfield Potential synergy between lipid-lowering and blood-pressure-lowering in the Anglo-Scandinavian Cardiac Outcomes Trial Eur Heart J 27 2006 2982 2988
20. P.S. Sever, B. Dahlof, N.R. Poultre, H. Wedel, G. Beevers, M. Caulfield ASCOT investigators Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentration, in the Anglo-Scandinavian Cardiac Outcome trial- Lipid Lowering Arm (ASCOT-LLA): a multicentre randomized controlled trial Lancet 361 2003 1149 1158 (Pubitemid 36398384)
21. Extended ASCOT-lipid lowering (ASCOT-LLA) study shows positive results of atorvastatin [editorial] Cardiovasc J Afr 19 2008 49 51
22. M. Brosa, R. Gisbert, J.M. Rodrguez, and J. Soto Principios, mtodos y aplicaciones del anlisis del impacto presupuestario en el sector sanitario Pharmacoeconomics Spa Res Articl 2 2005 65 79
23. D.A. Marshall, P.R. Douglas, M.F. Drummond, G.W. Torrance, S. Macleod, O. Manti, P. Lzaro, I. Mndez, and M. Garcia Vargas Guidelines for conducting pharmaceutical budget impact analyses for submission to public drug plans in Canada Pharmacoeconomics 26 2008 477 495
24. Ficha tcnica Caduet. Pfizer SA.
25. J. Fernndez de Bobadilla, C. Calvo, J.A. Gmez-Gerique, P. Lzaro, I. Mndez, and M. Garcia Vargas Coste por ao de vida ganado con atorvastatina 10 mg en pacientes hipertensos espaoles en riesgo moderado: Evaluacin econmica del estudio ASCOT-LLA con costes espaoles Pharmacoeconomics Spa Res Articl 4 2007 11 24
26. Instituto Nacional de Estadstica (INE). Proyecciones de poblacin estimadas para la regin (Padrn municipal 1 enero de 2006). Acceso: 15 de enero de 2009. (http://www.ine.es www.ine.es)
27. J.R. Banegas Banegas Epidemiologa de la hipertensin arterial en Espaa. Situacin actual y perspectivas Hipertensin 22 2005 353 362
28. V. Barrios, C. Escobar, J.L. Listerri, A. Caldern, E. Alegra, and J. Muiz Control de presin arterial y lpidos y riesgo coronario en la poblacin hipertensa asistida en Atencin primaria en Espaa. Estudio PRESCOT Rev Clin Esp 207 2007 172 178
29. R. Gabriel, R. Moreno, J. Garca-Puig, J.C. Abanades, R. Aristegui, and J. Fernandez de Bobadilla The metabolic Syndrome in the PALPITATES study (Prevalence of ASCOT-LIKE patient: Integral Territorial Assessment to obtain epidemiological data in Spain) Atherosclerosis (Suppls.) 9 2008 128
30. J.L. Llisterri, G.C. Rodrguez, F.J. Alonso, J.R. Banegas, D. Gonzlez-Segura, and S. Lou Control of blood pressure in Spanish hypertensive population attended in primary health-care. PRESCAP 2006 study Med Clin (Barc) 130 2008 681 687
31. Base de datos del Consejo General de Colegios Farmacuticos. Disponible en URL: http://www.portalfarma.com/home.nsf (acceso: 15 de enero 2009).
32. A. Sicras Mainar, J. Fernndez de Bobadilla, J. Rejas Gutirrez, and M. Garca Vargas Patrn de cumplimiento teraputico de antihipertensivos y/o hipolipemiantes en pacientes hipertensos y/o dislipmicos en Atencin Primaria An Med Interna 23 2006 1 14
33. J. Garca del Pozo, E. Ramos Sevillano, F.J. de Abajo, and R. Mateos Campos Utilizacin de antihipertensivos en espaa (19952001) Rev Esp Cardiol 57 2004 241 249
34. Grupo de trabajo para el manejo de la hipertensin arterial de la European Society of Hipertensin/ESH) y la European Society of Cardiology (ESC) Gua 2007 para el manejo de la Hipertensin J Hipertensin 25 2007 1105 1187
35. R. Jackson, C.M. Lawes, D.A. Bennett, R.J. Milne, and A. Rodgers Treatment with drugs to lower blood pressure and blood cholesterol based on an individual's absolute cardiovascular risk Lancet 365 2005 434 441
36. B.V. Patel, R.S. Leslie, P. Thiebaud, M.B. Nichols, S.S. Tang, and H. Solomon Adherence with single-pill amlodipine/atorvastatin versus a two-pill regimen Vasc Health Risk Manag 4 2008 673 681
37. F.D. Hobbs Can combining different risk interventions into a single formulation contribute to improved cardiovascular disease risk reduction? The single pill of amlodipine/atorvastatin. Vasc Health Risk Manag 3 2007 711 719
38. N. Howell, R. Trotter, D.R. Mottram, and P.H. Rowe Compliance with statins in primary care Pharm J 272 2004 223 226
39. P. Tricoci, J.M. Allen, J.M. Kramer, R.M. Califf, and S.C. Smith Jr Scientific evidence underlying the ACC/AHA clinical practice guidelines JAMA 301 2009 831 841
40. A. Sicras-Mainar, J. Fernndez de Bobadilla, R. Navarro-Artieda, and J. Rejas-Gutirrez Mortalidad por cualquier causa e incidencia de enfermedad cardiovascular en hipertensos con perfil ASCOT en un mbito poblacional espaol Aten Primaria 2010 (APRIM-D-09-00241, in press)